# Ronald Witteles

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ronald-witteles/

## Facts

| Field | Value |
| --- | --- |
| Citations | 14,385 |
| Field | Amyloidosis: Diagnosis, Treatment, Outcomes |
| h-index | 49 |
| i10-index | 116 |
| Last Known Institution | Alnylam Pharmaceuticals (United States) |
| OpenAlex ID | https://openalex.org/A5010445417 |
| ORCID iD | 0000-0002-3043-1472 |
| Works | 275 |

## Researcher papers

- [Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy](https://scholariq.org/papers/tafamidis-treatment-for-patients-with-transthyretin-amyloid-cardiomyopathy/)
- [Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations](https://scholariq.org/papers/management-of-cardiac-disease-in-cancer-patients-throughout-oncological/)
- [Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society](https://scholariq.org/papers/baseline-cardiovascular-risk-assessment-in-cancer-patients-scheduled-to-receive/)
- [Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity](https://scholariq.org/papers/human-induced-pluripotent-stem-cell-derived-cardiomyocytes-recapitulate-the/)
- [Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis](https://scholariq.org/papers/expert-consensus-recommendations-for-the-suspicion-and-diagnosis-of/)
- [Genotype and Phenotype of Transthyretin Cardiac Amyloidosis](https://scholariq.org/papers/genotype-and-phenotype-of-transthyretin-cardiac-amyloidosis/)
- [Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy](https://scholariq.org/papers/vutrisiran-in-patients-with-transthyretin-amyloidosis-with-cardiomyopathy/)
- [Insulin-Resistant Cardiomyopathy](https://scholariq.org/papers/insulin-resistant-cardiomyopathy/)
- [Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice](https://scholariq.org/papers/screening-for-transthyretin-amyloid-cardiomyopathy-in-everyday-practice/)
- [Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy](https://scholariq.org/papers/transthyretin-stabilization-by-ag10-in-symptomatic-transthyretin-amyloid/)
- [Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction](https://scholariq.org/papers/impact-of-nesiritide-on-renal-function-in-patients-with-acute-decompensated/)

## Researcher topics

- [Amyloidosis: Diagnosis, Treatment, Outcomes](https://scholariq.org/topics/amyloidosis-diagnosis-treatment-outcomes/)
- [Parathyroid Disorders and Treatments](https://scholariq.org/topics/parathyroid-disorders-and-treatments/)
- [Chemotherapy-induced cardiotoxicity and mitigation](https://scholariq.org/topics/chemotherapy-induced-cardiotoxicity-and-mitigation/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

## Researcher university

- [Alnylam Pharmaceuticals (United States)](https://scholariq.org/institutions/alnylam-pharmaceuticals-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.